Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645525 | 0.94 | NISCH (0.34) | NISCHMAPTHSP90AA1 | |
| SCHEMBL449107 | 0.74 | ALDH1A1 (0.44) | MAPT | |
| SCHEMBL20995461 | 0.74 | CYP11B2 (0.44) | NISCHMAPTCYP11B2HSP90AA1CYP2C9 | |
| SCHEMBL3154131 | 0.73 | ALDH1A1 (0.43) | MAPTHSP90AA1 | |
| SCHEMBL28761033 | 0.72 | CYP11B2 (0.47) | MAPTCYP11B2HSP90AA1CYP2C9EPHX2 | |
| SCHEMBL3135323 | 0.72 | CYP11B2 (0.47) | MAPTCYP11B2HSP90AA1CYP2C9EPHX2 | |
| SCHEMBL3003693 | 0.71 | NISCH (0.32) | NISCH | |
| SCHEMBL844231 | 0.71 | NISCH (0.39) | NISCH | |
| SCHEMBL28912987 | 0.70 | HSP90AA1 (0.34) | NISCHMAPTCYP11B2HSP90AA1 | |
| SCHEMBL28197535 | 0.70 | MAP4K4 (0.40) | NISCHCYP11B2HSP90AA1CYP2C9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | claimed |
| JP-2002539198-A | — | — | 2002-11-19 | — | — | JP | claimed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2017029498-A1 | 2-SULFONYLPYRIMIDINES | MEDICAL RESEARCH COUNCIL (GB) | 2017-02-23 | — | — | WO | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2475643-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011026959-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-7276491-B2 | Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2003084539-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | NISCH 3202/4885MAPT 3266/4885CYP11B2 93/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | NISCH 1070/4885MAPT 3138/4885CYP11B2 246/4885 |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | TNF, IL2, IL1B | NISCH 1613/4885MAPT 911/4885CYP11B2 1642/4885 |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | NISCH 298/4885MAPT 4745/4885CYP11B2 472/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | NISCH 1070/4885MAPT 3138/4885CYP11B2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.